Earnings

The company attributed the operational revenue decrease of USD 57 million to lower COVID-19 product, Prevnar family and other revenues, largely offset by growth in Eliquis, Padcev, the Vyndaqel family, Nurtec ODT/Vydura and Lorbrena. Eliquis revenue rose to USD 2.523 billion from USD 2.015 …

Revenues fell on lower strategic advisory, restructuring and privateCapitalsolutions revenues, partly offset by higher primary fundraising revenues. Adjusted compensation and benefits expense dropped 15% to USD 256.1 million, or 66.5% of revenues versus 67.5%, on lower revenues and a lower accrual rate. Adjusted non-compensation …

The company attributed the increase mainly to higher customer usage and growth and to weather, partly offset by higherDepreciationand amortization, higher interest charges and lower other income. Nine month diluted EPS was USD 5.20 against USD 4.93.

On a GAAP basis the company posted a net loss attributable to the company of USD 12.5 million, or USD 0.19 per diluted share, againstNet Incomeof USD 79.6 million, or USD 1.20 per share, a year earlier. A non-cash goodwill impairment of USD 119.3 …

Pro forma revenue growth and pro forma organic growth were both 7%. President and Chief Executive Officer Prahlad Singh said results came in meaningfully ahead of company projections, with improving end markets, a pipeline of new products and transformation benefits showing up in results.

Sales grew 29% from the second quarter, and patients on reimbursed therapy worldwide increased 20% over the same period. Chairman, Chief Executive Officer and President David Meeker pointed to the United States launch in acquired hypothalamic obesity, approved by the FDA on March 19, …

Chief Executive Officer Alton Shader pointed to solid constant currency growth at the top and bottom lines and to nearly 100 basis points of sequential adjusted EBITDAMarginexpansion. He also highlighted constant currency revenue growth of 8.2% at Sterigenics and 9.2% at Nelson Labs.